J Gynecol Oncol.  2014 Oct;25(4):352-354. 10.3802/jgo.2014.25.4.352.

Prognostic impact of epithelial cell adhesion molecule in ovarian cancer patients

• Lee M

• KMID: 2130126
• DOI: http://doi.org/10.3802/jgo.2014.25.4.352

Abstract

No abstract available.

MeSH Terms

Antigens, Neoplasm/*metabolism
Antineoplastic Agents/*therapeutic use
Cell Adhesion Molecules/*metabolism
Female
Humans
Neoplasms, Glandular and Epithelial/*diagnosis
Organoplatinum Compounds/*therapeutic use
Ovarian Neoplasms/*diagnosis
Tumor Markers, Biological/*metabolism
Antigens, Neoplasm
Antineoplastic Agents
Cell Adhesion Molecules
Organoplatinum Compounds
Tumor Markers, Biological

Reference

1. Baeuerle PA, Gires O. EpCAM (CD326) finding its role in cancer. Br J Cancer. 2007; 96:417–423.

2. Patriarca C, Macchi RM, Marschner AK, Mellstedt H. Epithelial cell adhesion molecule expression (CD326) in cancer: a short review. Cancer Treat Rev. 2012; 38:68–75.

3. Woopen H, Pietzner K, Richter R, Fotopoulou C, Joens T, Braicu EI, et al. Overexpression of the epithelial cell adhesion molecule is associated with a more favorable prognosis and response to platinum-based chemotherapy in ovarian cancer. J Gynecol Oncol. 2014; 25:221–228.

4. Bellone S, Siegel ER, Cocco E, Cargnelutti M, Silasi DA, Azodi M, et al. Overexpression of epithelial cell adhesion molecule in primary, metastatic, and recurrent/chemotherapy-resistant epithelial ovarian cancer: implications for epithelial cell adhesion molecule-specific immunotherapy. Int J Gynecol Cancer. 2009; 19:860–866.

5. Spizzo G, Went P, Dirnhofer S, Obrist P, Moch H, Baeuerle PA, et al. Overexpression of epithelial cell adhesion molecule (Ep-CAM) is an independent prognostic marker for reduced survival of patients with epithelial ovarian cancer. Gynecol Oncol. 2006; 103:483–488.

6. Spizzo G, Went P, Dirnhofer S, Obrist P, Simon R, Spichtin H, et al. High Ep-CAM expression is associated with poor prognosis in node-positive breast cancer. Breast Cancer Res Treat. 2004; 86:207–213.

7. Varga M, Obrist P, Schneeberger S, Muhlmann G, Felgel-Farnholz C, Fong D, et al. Overexpression of epithelial cell adhesion molecule antigen in gallbladder carcinoma is an independent marker for poor survival. Clin Cancer Res. 2004; 10:3131–3136.

8. Went P, Dirnhofer S, Salvisberg T, Amin MB, Lim SD, Diener PA, et al. Expression of epithelial cell adhesion molecule (EpCam) in renal epithelial tumors. Am J Surg Pathol. 2005; 29:83–88.

9. Went P, Vasei M, Bubendorf L, Terracciano L, Tornillo L, Riede U, et al. Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers. Br J Cancer. 2006; 94:128–135.

10. Heiss MM, Murawa P, Koralewski P, Kutarska E, Kolesnik OO, Ivanchenko VV, et al. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II/III trial. Int J Cancer. 2010; 127:2209–2221.

11. Ott MG, Marme F, Moldenhauer G, Lindhofer H, Hennig M, Spannagl R, et al. Humoral response to catumaxomab correlates with clinical outcome: results of the pivotal phase II/III study in patients with malignant ascites. Int J Cancer. 2012; 130:2195–2203.

12. Gutzmer R, Li W, Sutterwala S, Lemos MP, Elizalde JI, Urtishak SL, et al. A tumor-associated glycoprotein that blocks MHC class II-dependent antigen presentation by dendritic cells. J Immunol. 2004; 173:1023–1032.